Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) shares saw unusually-high trading volume on Wednesday . Approximately 363,087 shares were traded during trading, an increase of 52% from the previous session’s volume of 238,715 shares.The stock last traded at $13.65 and had previously closed at $14.30.

ADMS has been the subject of several recent analyst reports. Noble Financial reiterated a “buy” rating and set a $25.00 price objective on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 28th. Credit Suisse Group AG reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 22nd. Mizuho reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Thursday, June 23rd. JMP Securities reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 15th. Finally, Cowen and Company restated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Thursday, May 12th. Two equities research analysts have rated the stock with a sell rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $32.00.

The firm’s market capitalization is $300.87 million. The stock’s 50-day moving average price is $14.64 and its 200 day moving average price is $15.31.

An institutional investor recently raised its position in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP increased its position in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned 0.38% of Adamas Pharmaceuticals worth $1,966,000 as of its most recent filing with the SEC.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.